This content is in French.
FOXC1: The GPS for Capecitabine in TNBC?
29 octobre 2025
By Ana Espino | Published on October 29, 2025 | 3 min readTriple-negative breast cancer (TNBC) is an aggressive form of the disease, often diagnosed in young women, that does not respond to hormone therapy or HER2-targeted treatments. Therapeutic options are mainly limited to cytotoxic chemotherapy, which shows variable efficacy and notable side effects. Among the available agents, capecitabine is
Triple-negative breast cancer (TNBC) is an aggressive form of the disease, often diagnosed in young women, that does not respond to hormone therapy or HER2-targeted treatments. Therapeutic options are mainly limited to cytotoxic chemotherapy, which shows variable efficacy and notable side effects. Among the available agents, capecitabine is widely prescribed as adjuvant therapy or for recurrent disease, but its clinical benefit varies considerably between patients.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
Rojo, F., et al. FOXC1 Expression Predicts Capecitabine Efficacy in Patients with Triple-Negative Breast Cancer from the GEICAM_CIBOMA Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(17), 3715–3724
View the source
